France Implements New Early Access Pathway For Innovative Medicines
Current Procedures Have Become Too Complex, Says Health Ministry
Reforms to the French early access processes will make reimbursement decisions more predictable and bring greater consistency into the medicinal product pathway says the French pharmaceutical industry body Leem. Others, though, say the system is too complicated and lacks clarity in a number of areas.
You may also be interested in...
Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.
The EMA is going all out to maximize coverage of the EU population with both vaccines and treatments for COVID-19.
Drug sponsors seeking centralized EU marketing authorizations now have the opportunity to have simpler pre-submission “interactions” with the European Medicines Agency six months before the submission to help avoid complications down the line. Full meetings may still be appropriate for complex issues such as requests for accelerated assessment or conditional approval.